Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 616-617

  Sterba, Jaroslav ^a   Pavelka, Zdenek ^a   Andre, Nicolas ^b   Ventruba, Jiri ^a   Skotakova, Jarmila ^a   Bajciova, Viera ^a   Bronisova, Danica ^a   Dubska, Lenka ^c   Valik, Dalibor ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b TIMONE HOSPITAL   (France)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Metronomic chemotherapy; Relapsed medulloblastoma

Indexed keywords

CELECOXIB; COLECALCIFEROL; CYTOSTATIC AGENT; FENOFIBRATE; ISOTRETINOIN; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHILD; DRUG WITHDRAWAL; EDEMA; FRONTAL LOBE; GRAND MAL SEIZURE; HISTOPATHOLOGY; HUMAN; LUMBAR PUNCTURE; MALE; MEDULLOBLASTOMA; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CRANIAL FOSSA TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CEREBELLAR NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DRUG CHRONOTHERAPY; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; REMISSION INDUCTION;

EID: 77649153801     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22382     Document Type: Article

References (19)

1. Butturini AM, Jacob M, Aguajo J, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: The impact of prior radiotherapy on outcome. Cancer 2009;115:2956-2963.
2. Cheuk DK, Lee TL, Chiang AK, et al. Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children. J Neurooncol 2008;86:337-347.
3. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008;50:970-975.
4. Grodman H, Wolfe L, Kretschmar C, Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer 2009;53:33-36.
5. Andre N, Pasquier E, Verschuur A, et al. Metronomic chemotherapy in pediatric oncology: Hype or hope? Arch Pediatr 2009;16:1158-1165.
6. Chang CH, Housepian EM, Herbert C, Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-1359.
7. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002;49:117-120.
8. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (st jude medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
9. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009;27:1007-1013.
10. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study. Onkologie 2006;29:308-313.
11. NIH. Common terminology criteria for adverse events. 2003. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcae-index.pdf#search=p.
12. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
13. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24.
14. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
15. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.
16. Lam T, Hetherington JW, Greenman J, et al. From total empiricism to a rational design of metronomic chemotherapy phase i dosing trials. Anticancer Drugs 2006;17:113-121.
17. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-3061.
18. Beyer M, Schultze JL. Regulatory t cells: Major players in the tumor microenvironment. Curr Pharm Des 2009;15:1879-1892.
19. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 2009;119: 2127-2130.